Search Result

Results for "

LXRα

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (4) Caspase (2) Drug Metabolite (1) Endogenous Metabolite (1) Estrogen Receptor/ERR (2) Fatty Acid Synthase (FASN) (1) Free Fatty Acid Receptor (1) Fungal (2) FXR (3) G protein-coupled Bile Acid Receptor 1 (1) Glucocorticoid Receptor (2) Heme Oxygenase (HO) (1) Interleukin Related (3) JNK (1) Keap1-Nrf2 (3) Lipase (1) LXR (29) NO Synthase (1) PARP (2) PPAR (1) Quinone Reductase (1) RAR/RXR (1) Reference Standards (7) ROR (3) Sirtuin (1) Stearoyl-CoA Desaturase (SCD) (1) TNF Receptor (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (15) Endocrinology (3) Infection (2) Inflammation/Immunology (7) Metabolic Disease (20) Neurological Disease (3)
Oligonucleotides:	Nucleoside Analogs (1) Inosine (1)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10626

T0901317 Maximum Cited Publications 44 Publications Verification	LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 is an orally active and highly selective *LXR* agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-10629

LXR-623 10+ Cited Publications WAY 252623	LXR	Metabolic Disease Cancer
LXR-623 is a brain-penetrant partial *LXRα* and full LXRβ agonist, with IC₅₀s of 24 nM and 179 nM, respectively.

HY-108688

GSK2033 30+ Cited Publications	LXR	Metabolic Disease
GSK2033 is a *LXR* antagonist with pIC₅₀s of 7 and 7.4 for *LXRα* or LXRβ, respectively.

HY-N1178

Taraxasterol 4 Publications Verification	Interleukin Related LXR	Inflammation/Immunology
Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an *LXRα* activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases .

HY-N0835

(20S)-Protopanaxatriol 1 Publications Verification 20(S)-APPT; g-PPT	Glucocorticoid Receptor Estrogen Receptor/ERR LXR Apoptosis	Cardiovascular Disease Endocrinology Cancer
(20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a *LXRα* inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects .

HY-19919

BMS-779788 1 Publications Verification EXEL04286652; XL-652; BMS-788	LXR	Metabolic Disease
BMS-779788 is a *LXR* partial agonist with IC₅₀ values of 68 nM for LXRα and 14 nM for LXRβ.

HY-112813

TUG-1375 4 Publications Verification	Free Fatty Acid Receptor	Metabolic Disease
TUG-1375 is an agonist of free fatty acid receptor 2 (FFA2/GPR43), with a pK_i of 6.69. TUG-1375 is inactive on FFA3, FFA4, PPARα, PPARγ, PPARδ, LXRα or LXRβ .

HY-18282

AZ876	LXR	Cardiovascular Disease Metabolic Disease Cancer
AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (K_i=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis .

HY-101442

SR9238 2 Publications Verification	LXR	Metabolic Disease
SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC₅₀s of 214 nM and 43 nM for *LXRα* and LXRβ, respectively.

HY-N1970

5,7-Dihydroxychromone 2 Publications Verification	Keap1-Nrf2 Caspase PARP Fungal	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
5,7-Dihydroxychromone is a flavonoid compound with antioxidant properties. 5,7-Dihydroxychromone induces Nrf2 nuclear translocation, increases Nrf2/ARE binding activity, and up-regulates Nrf2-dependent antioxidant genes HO-1, NQO1, GCLc. 5,7-Dihydroxychromone attenuates excessive ROS generation, inhibits activated caspase-3, caspase-9, cleaved PARP expression, and prevents neuronal apoptosis and cell death. 5,7-Dihydroxychromone increases LXRα and PPARγ mRNA expression, induces preadipocyte differentiation, and regulates blood glucose levels. 5,7-Dihydroxychromone inhibits radial growth of soil pathogenic fungi, radicle elongation of select seedlings, and transiently inhibits Bradyrhizobium sp. growth in high mannitol medium. 5,7-Dihydroxychromone can be used for the research of Parkinson’s disease, type 2 diabetes mellitus and pathogenic fungal infection .

HY-128671

6-Thioinosine 6TI; 6-Mercaptopurine riboside	PPAR LXR JNK NO Synthase	Metabolic Disease
6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of PPARγ and C/EBPα and downregulates the mRNA levels of PPARγ target genes (LPL, CD36, aP2, and *LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating PPARγ* through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction .

HY-144549

LXR agonist 1	LXR	Cardiovascular Disease
LXR (Liver X receptor) agonist 1 is potent *LXR* agonist with AC₅₀s of 1.5 nM and 12 nM for *LXR-α* and *LXR-β, respectively. LXR* agonist 1 has the potential for the research of atherosclerosis .

HY-123148

IMB-808	LXR	Inflammation/Immunology
IMB-808 is a potent LXRα/β dual agonist with EC₅₀ values of 0.53 μM and 0.15 μM (0.15 μM, using GAL4-pGL4-luc reporter plasmid) for LXRβ and LXRα, respectively. IMB-808 promotes expression of genes related to reverse cholesterol transport (ABCA1 and ABCG1). IMB-808 can be used for the study of atherosclerosis research .

HY-117006

E1231 1 Publications Verification 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE ^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .

HY-117549

Ibrolipim NO-1886	Lipase	Cardiovascular Disease
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects .

HY-N2509

Iristectorigenin B Iristectrigenin B	LXR	Cardiovascular Disease
Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β .

HY-W587772

Mono(2-ethyl-5-hydroxyhexyl) terephthalate MEHHTP	Drug Metabolite	Metabolic Disease
Mono (2-ethyl-5-hydroxyhexyl) terephthalate (MEHHTP), a hydroxyl metabolite of the phthalate alternative Di-2-ethylhexyl terephthalate (DEHTP), is a liver X receptor α (LXRα) agonist with a binding energy of -7.41 kcal/mol. Mono (2-ethyl-5-hydroxyhexyl) terephthalate upregulates LXRα downstream targets such as SREBP-1c and FASN and increases lipogenic enzyme activity in hepatocytes, and elevating triglyceride (TG) levels. Mono (2-ethyl-5-hydroxyhexyl) terephthalate is promising for research of nonalcoholic fatty liver disease (NAFLD) .

HY-139067

25(S)-27-Hydroxy cholesterol	LXR	Cardiovascular Disease
25(S)-27-Hydroxy cholesterol is a metabolite of CYP27A1 mediated cholesterol hydroxylation. 25(S)-27-Hydroxy cholesterol inhibits melanoma cell proliferation .

HY-143259

BE1218	LXR	Cancer
BE1218 is a liver X receptor (LXR) inverse agonist with IC₅₀ values of 9 nM and 7 nM against LXRα and LXRβ, respectively .

HY-136527

BMS-986251	ROR Interleukin Related	Inflammation/Immunology
BMS-986251 is an orally active and selective RORγt inverse agonist with an EC₅₀ of 12 nM for RORγt GAL4. BMS-986251 inhibits IL-17 with an EC₅₀ of 24 nM in human whole blood assay. BMS-986251 demonstrates robust efficacy in mouse acanthosis and Imiquimod-induced (HY-B0180) models (preclinical models of psoriasis) .

HY-133830

7α,24(S)-Dihydroxycholesterol (3β,7α,24S)-Cholest-5-ene-3,7,24-triol	Endogenous Metabolite	Others
7α,24(S)-Dihydroxycholesterol ((3β,7α,24S)-Cholest-5-ene-3,7,24-triol) serves as a ligand for liver X receptor (LXR), binding specifically to the ligand binding domains of both LXRα and LXRβ. This compound is synthetically produced from E-α,β-enone, utilizing Arsonium ylide and J-tert-butyldimethylsilyloxy-bisnor-5-cholenaldehyde as starting materials, followed by a series of transformations to yield 7α,24(S)-dihydroxycholesterol.

HY-N2273

Gymnestrogenin	LXR	Metabolic Disease
Gymnestrogenin is a pentahydroxytriterpene from the leaves of Gymnema sylvestre R.Br . Gymnestrogenin is a *LXR* antagonist with IC₅₀s of 2.5 and 1.4 μM for LXRα and LXRβ transactivation, respectively. Gymnestrogenin reduces the transcriptional activity of LXR even on its own promoter, thus reducing the mRNA expression .

HY-134969

TFCA	LXR	Metabolic Disease
TFCA is a liver X receptor α (LXRα) antagonist. TFCA inhibits ligand-activated LXRα coactivation and transcriptional expression of the downstream target genes involved in fatty acid synthesis. TFCA attenuates ligand-induced lipogenesis and fatty liver by selectively inhibiting LXRα in the liver .

HY-10626R

T0901317 (Standard)	Reference Standards LXR FXR ROR Apoptosis	Cardiovascular Disease Metabolic Disease Cancer
T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα . T0901317 activates FXR with an EC50 of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

HY-179278

LXR agonist 4	LXR	Cardiovascular Disease Metabolic Disease Endocrinology
LXR agonist 4 is a selective *LXR* inverse agonist with IC₅₀ values of 7.6 (LXRα) and 2.9 μM (LXRβ), respectively. LXR agonist 4 exhibits selectivity over RORα and FXR. LXR agonist 4 robustly suppresses SREBP1c expression without altering ABCA1 or APOE. LXR agonist 4 displays antilipogenic properties and resolves fatty acid-induced steatosis. LXR agonist 4 can be used for the research of atherosclerosis and metabolic dysfunction-associated steatotic liver disease (MASLD) .

HY-185104

Ginsenoside C-K hexapropionate ester	LXR	Cardiovascular Disease
Ginsenoside C-K hexapropionate ester (Structure 2) is a selective agonist of *LXRα, with no significant activation effect on LXRβ. Ginsenoside C-K hexapropionate ester upregulates the expression of downstream genes such as ABCA1* by activating *LXRα, promoting reverse cholesterol transport, and reducing lipid deposition in macrophage-derived foam cells. It can be used in the research of atherosclerosis. Ginsenoside C-K hexapropionate ester is a derivative synthesized from ginsenoside Compound K, an active metabolite of Panax notoginseng* saponins, by modification with propionic anhydride .

HY-N1178R

Taraxasterol (Standard)	Others Interleukin Related LXR Reference Standards	Inflammation/Immunology
Taraxasterol (Standard) is the analytical standard of Taraxasterol. This product is intended for research and analytical applications. Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an LXRα activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases .

HY-173393

LXRα agonist 1	LXR	Cancer
LXRα agonist 1 (Compound 40) is a selective *LXRα* agonist (EC₅₀: 42 nM). LXRα agonist 1 also has a certain agonistic effect on LXRβ (EC₅₀: 266 nM). LXRα agonist 1 promotes target gene transcription by stabilizing the ligand binding domain (LBD) of LXRα. LXRα agonist 1 exhibits potent antitumor effects in hepatocellular carcinoma cells when combined with the Raf inhibitor Sorafenib (HY-10201). LXRα agonist 1 can be used in the study of lipotoxic cancers .

HY-170570

PFM046	LXR Stearoyl-CoA Desaturase (SCD) Fatty Acid Synthase (FASN)	Cancer
PFM046 is the antagonist for liver X receptor (LXR), that inhibits the activation of *LXRα* and LXRβ with IC₅₀ of 2.04 μM and 1.58 μM. PFM046 inhibits the expression of SCD1 and FASN, upregulates the expression of ABCA1, and exhibits antitumor efficacy in mouse models .

HY-18282R

AZ876 (Standard)	LXR	Cardiovascular Disease Metabolic Disease Cancer
AZ876 (Standard) is the analytical standard of AZ876. This product is intended for research and analytical applications. AZ876 is a selective, orally active agonist of liver X receptor (LXRα/β) (Ki=0.007 μM [LXRα, human], 0.011 μM [LXRβ, human]. AZ876 induces the expression of target genes such as ABCA1 and ABCG1, promotes reverse cholesterol transport (RCT) and regulates lipid metabolism and anti-inflammatory effects. AZ876 increases cardiac polyunsaturated fatty acid levels, reduces myocardial fibrosis, and reduces lesion area and monocyte adhesion in atherosclerosis models. AZ876 can be used in cardiovascular disease research, such as preventing and treating β-adrenergic-induced cardiac diastolic dysfunction and inhibiting the progression of atherosclerosis .

HY-N1970R

5,7-Dihydroxychromone (Standard)	Reference Standards Keap1-Nrf2 Caspase PARP Fungal	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
5,7-Dihydroxychromone (Standard) is the analytical standard of 5,7-Dihydroxychromone (HY-N1970). This product is intended for research and analytical applications. 5,7-Dihydroxychromone is a flavonoid compound with antioxidant properties. 5,7-Dihydroxychromone induces Nrf2 nuclear translocation, increases Nrf2/ARE binding activity, and up-regulates Nrf2-dependent antioxidant genes HO-1, NQO1, GCLc. 5,7-Dihydroxychromone attenuates excessive ROS generation, inhibits activated caspase-3, caspase-9, cleaved PARP expression, and prevents neuronal apoptosis and cell death. 5,7-Dihydroxychromone increases LXRα and PPARγ mRNA expression, induces preadipocyte differentiation, and regulates blood glucose levels. 5,7-Dihydroxychromone inhibits radial growth of soil pathogenic fungi, radicle elongation of select seedlings, and transiently inhibits Bradyrhizobium sp. growth in high mannitol medium. 5,7-Dihydroxychromone can be used for the research of Parkinson’s disease, type 2 diabetes mellitus and pathogenic fungal infection .

HY-N12619

12R,13S-Dihydroxyfumitremorgin C	LXR	Cancer
12R,13S-Dihydroxyfumitremorgin C (compound 1) is a *LXRα* agonist .

HY-101442R

SR9238 (Standard)	Reference Standards LXR	Metabolic Disease
SR9238 (Standard) is the analytical standard of SR9238. This product is intended for research and analytical applications. SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC50s of 214 nM and 43 nM for LXRα and LXRβ, respectively.

HY-10629R

LXR-623 (Standard) WAY 252623 (Standard)	Reference Standards LXR	Metabolic Disease Cancer
LXR-623 (Standard) is the analytical standard of LXR-623. This product is intended for research and analytical applications. LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.

HY-121671

TBTC	RAR/RXR	Neurological Disease
TBTC is a selective agonist with the activity of improving behavioral deficits in Alzheimer's disease model mice. TBTC can effectively activate the heterodimerization of RXRα with LXRα or PPARγ. TBTC stimulates the expression of apoE, ABCA1, and ABCG1 genes and reduces Aβ content in cells and animal models .

HY-N0835R

(20S)-Protopanaxatriol (Standard) 20(S)-APPT (Standard); g-PPT (Standard)	Reference Standards Glucocorticoid Receptor Estrogen Receptor/ERR LXR Apoptosis	Cardiovascular Disease Endocrinology Cancer
(20S)-Protopanaxatriol (Standard) is the analytical standard of (20S)-Protopanaxatriol. This product is intended for research and analytical applications. (20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a LXRα inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects .

HY-182014

TLC-2716	LXR	Cardiovascular Disease Metabolic Disease
TLC-2716 is an orally available, gut- and liver-restricted inhibitor against *LXRα* and LXRβ, with EC₅₀ values of 7 nM and 15 nM, respectively. TLC-2716 represses LXRα/β transcriptional activity, downregulates genes involved in lipogenesis, lipid absorption and lipoprotein metabolism, and preserves peripheral reverse cholesterol transport. TLC-2716 reduces lipid accumulation, suppresses inflammation and fibrotic gene expression, enhances triglyceride-rich lipoprotein clearance, and improves glucose homeostasis and insulin sensitivity. TLC-2716 lowers serum and hepatic triglycerides, plasma cholesterol and other atherogenic lipid profiles in experimental models and humanized liver mice. TLC-2716 can be used for the research of dyslipidemia and related cardiometabolic disorders .

HY-108688R

GSK2033 (Standard)	Reference Standards LXR	Metabolic Disease
GSK2033 (Standard) is the analytical standard of GSK2033 (HY-108688). This product is intended for research and analytical applications. GSK2033 is a LXR antagonist with pIC₅₀s of 7 and 7.4 for LXRα or LXRβ, respectively.

HY-183692

FXR agonist 18	FXR G protein-coupled Bile Acid Receptor 1 TNF Receptor Heme Oxygenase (HO) Quinone Reductase Keap1-Nrf2	Cardiovascular Disease Inflammation/Immunology
FXR agonist 18 is an orally active FXR agonist, with an EC₅₀ of 10 nM against human FXR and an EC₅₀ of 1360 nM against human TGR5. FXR agonist 18 inhibits inflammatory responses by reducing nitrite production, downregulating the expression of pro-inflammatory genes (Tnf, Adgre1, Cyp8b1, upregulating the expression of FXR, Hmox1, Nqo1, Nrf2, and enhancing antioxidant responses. FXR agonist 18 ameliorates liver fibrosis in mice, exhibits protective effects in mice with cholestatic liver injury, and shows anti-MASH efficacy. FXR agonist 18 can be used in studies of metabolic dysfunction-associated steatohepatitis .

Taraxasterol 4 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Astragalus oleifolius DC. Plants Compositae Inflammation/Immunology Disease Research Fields	Interleukin Related LXR
Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an *LXRα* activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases .

(20S)-Protopanaxatriol 1 Publications Verification 20(S)-APPT; g-PPT	Panax ginseng C. A. Meyer Cardiovascular Disease Triterpenes Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Glucocorticoid Receptor Estrogen Receptor/ERR LXR Apoptosis
(20S)-Protopanaxatriol is a metabolite of ginsenoside. (20S)-Protopanaxatriol works through the glucocorticoid receptor (GR) and estrogen receptor (ER), and is also a *LXRα* inhibitor. (20S)-Protopanaxatriol shows a broad spectrum of antitumor effects .

5,7-Dihydroxychromone 2 Publications Verification	Structural Classification Flavonoids other families Phenols Polyphenols Plants Isoflavones Source Classification	Keap1-Nrf2 Caspase PARP Fungal
5,7-Dihydroxychromone is a flavonoid compound with antioxidant properties. 5,7-Dihydroxychromone induces Nrf2 nuclear translocation, increases Nrf2/ARE binding activity, and up-regulates Nrf2-dependent antioxidant genes HO-1, NQO1, GCLc. 5,7-Dihydroxychromone attenuates excessive ROS generation, inhibits activated caspase-3, caspase-9, cleaved PARP expression, and prevents neuronal apoptosis and cell death. 5,7-Dihydroxychromone increases LXRα and PPARγ mRNA expression, induces preadipocyte differentiation, and regulates blood glucose levels. 5,7-Dihydroxychromone inhibits radial growth of soil pathogenic fungi, radicle elongation of select seedlings, and transiently inhibits Bradyrhizobium sp. growth in high mannitol medium. 5,7-Dihydroxychromone can be used for the research of Parkinson’s disease, type 2 diabetes mellitus and pathogenic fungal infection .

Iristectorigenin B Iristectrigenin B	Cardiovascular Disease Natural Products Iridaceae Classification of Application Fields Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Disease Research Fields Source Classification	LXR
Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β .

Gymnestrogenin	Triterpenes Classification of Application Fields Terpenoids Asclepiadaceae Metabolic Disease Plants Disease Research Fields Gymnema sylvestre (Retz.) Schult. Source Classification	LXR
Gymnestrogenin is a pentahydroxytriterpene from the leaves of Gymnema sylvestre R.Br . Gymnestrogenin is a *LXR* antagonist with IC₅₀s of 2.5 and 1.4 μM for LXRα and LXRβ transactivation, respectively. Gymnestrogenin reduces the transcriptional activity of LXR even on its own promoter, thus reducing the mRNA expression .

Taraxasterol (Standard)	Triterpenes Structural Classification Classification of Application Fields Terpenoids Astragalus oleifolius DC. Plants Compositae Inflammation/Immunology Disease Research Fields Source Classification	Others Interleukin Related LXR Reference Standards
Taraxasterol (Standard) is the analytical standard of Taraxasterol. This product is intended for research and analytical applications. Taraxasterol is a pentacyclic triterpenoid compound isolated from Taraxacum mongolicum. Taraxasterol is an LXRα activator, with metabolic and anti-inflammatory effects. Taraxasterol may be used in research on immune-inflammatory diseases .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P701404

	LXR-α Protein, Human NR1H3; Oxysterols receptor LXR-alpha; Liver X receptor alpha; Nuclear receptor subfamily 1 group H member 3	Human	E. coli
	LXR-α protein is a nuclear receptor that activates transcription by interacting with RXR. It regulates cholesterol uptake through MYLIP-dependent ubiquitination and is critical for cholesterol homeostasis. LXR-α Protein, Human is the recombinant human-derived LXR-α protein, expressed by E. coli , with tag free.

HY-P701405

	LXR-α Protein, Human (His) NR1H3; Oxysterols receptor LXR-alpha; Liver X receptor alpha; Nuclear receptor subfamily 1 group H member 3	Human	E. coli
	LXR-α protein is a nuclear receptor that activates transcription by interacting with RXR. It regulates cholesterol uptake through MYLIP-dependent ubiquitination and is critical for cholesterol homeostasis. LXR-α Protein, Human (His) is the recombinant human-derived LXR-α protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87801

	LXRα Antibody (YA7486)	WB, ICC/IF, ELISA	Human, Mouse, Rat
	LXRα Antibody (YA7486) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to LXRα.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-128671

6-Thioinosine 6TI; 6-Mercaptopurine riboside		Nucleoside Analogs Inosine
6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of PPARγ and C/EBPα and downregulates the mRNA levels of PPARγ target genes (LPL, CD36, aP2, and *LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating PPARγ* through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

LXRα

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products